Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom.

Hera SandhuWeiwei XuAnamaria-Vera OlivieriChristopher LübkerInger SmithVasileios Antavalis

Published in: Advances in therapy (2023)

Semaglutide 2.4 mg s.c. injection is a cost-effective therapy compared to D&E alone for patients with obesity and weight-related comorbidities in the UK. Sensitivity and scenario analyses confirm the robustness of the analyses.

Keyphrases

weight loss
weight gain
body mass index
ultrasound guided
physical activity
metabolic syndrome
insulin resistance
cross sectional
type diabetes
body weight
high fat diet induced
stem cells
skeletal muscle
drug induced